BC051070 Activators
BC051070 Activators are a diverse set of chemical compounds that, through various signaling mechanisms, are hypothesized to enhance the functional activity of the protein BC051070. Forskolin, by increasing intracellular cAMP, activates the PKA signaling cascade that could phosphorylate BC051070, thus enhancing its function. Similarly, PMA activates PKC, which may modulate BC051070 activity through phosphorylation-dependent mechanisms. CREB1 Activators comprise an array of chemical compounds that enhance the functional activity of the transcription factor CREB1 through different intracellular signaling pathways. Forskolin, IBMX, Rolipram, Sp-cAMPS, 8-Br-cAMP, and BAY 73-6691 all act to increase intracellular cAMP levels, either by direct activation of adenylate cyclase or inhibition of phosphodiesterases, leading to the activation of PKA.
Once activated, PKA phosphorylates CREB1 at Ser133, a critical residue for CREB1's transcriptional activity, thereby enhancing its function in gene expression. Similarly, PMA activates PKC, which may also phosphorylate CREB1 at distinct sites, contributing to its activation. Sildenafil, by inhibiting PDE5, raises cGMP levels and activates PKG, which could further phosphorylate CREB1 and potentiate its transcriptional activity. Additionally, curcumin, known for its wide range of biological effects, activates PKA, thereby promoting CREB1 phosphorylation and activation. Complementing these cAMP and cGMP-mediated mechanisms, other CREB1 Activators work through distinct molecular pathways. Nicotinamide, by inhibiting the deacetylase activity of SIRT1, may enhance CREB1 activity through acetylation-dependent processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC). Activation of PKC could lead to phosphorylation events that enhance the function of BC051070 if it is a substrate or is regulated by PKC-mediated signaling. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels. The rise in calcium may activate calcium-dependent kinases, such as CaMKII, potentially leading to the activation of BC051070 if it is part of calcium-regulated pathways. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a tyrosine kinase inhibitor that could prevent phosphorylation of proteins that negatively regulate BC051070, leading to its increased activity if BC051070 is negatively controlled by tyrosine kinase signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that could shift signaling dynamics to enhance the activity of BC051070 if it is regulated by pathways involving PI3K or downstream elements like Akt. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK, which could upregulate BC051070 activity indirectly if BC051070 is part of a signaling cascade that is negatively influenced by p38 MAPK activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that could indirectly enhance the function of BC051070 if it is downstream of or regulated by the ERK/MAPK signaling pathway. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore that increases intracellular calcium levels, possibly activating pathways or proteins that enhance BC051070 activity if it is regulated by calcium signaling. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast is another PDE5 inhibitor that, like sildenafil, increases cGMP levels, potentially activating signaling pathways that could enhance the activity of BC051070. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective PDE4 inhibitor that increases cAMP levels, potentially leading to the activation of cAMP-dependent pathways that enhance the activity of BC051070. | ||||||